Reassuring Data for High-Efficacy MS Meds in Pregnancy

Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system that predominantly affects women of childbearing age. The decision to continue or discontinue disease-modifying therapies (DMTs) during pregnancy is complex, balancing the risk of MS relapse and progression against potential fetal exposure. High-efficacy DMTs, while effective in controlling disease activity, have historically been associated with greater caution regarding periconceptional and gestational use due to limited safety data. This has often led to treatment cessation, potentially increasing the risk of postpartum relapses and long-term disability accumulation for the mother. The prevalence of MS in women of reproductive age underscores the critical need for robust safety data on DMTs during pregnancy to inform clinical decision-making and patient counseling. Approximately two-thirds of individuals diagnosed with MS are women, with onset typically occurring between the ages of 20 and 40 years, coinciding with peak childbearing years. Managing MS during pregnancy requires a careful assessment of individual disease activity, prior treatment response, and patient preferences, all while prioritizing maternal and fetal well-being.

Safety Data for Natalizumab and Ocrelizumab in Pregnancy

Recent observational data have provided reassuring insights into the pregnancy outcomes following exposure to natalizumab and ocrelizumab. Natalizumab, a humanized monoclonal antibody targeting α4-integrin, prevents leukocyte migration into the central nervous system. This mechanism of action specifically inhibits the adhesion and transmigration of inflammatory cells across the blood-brain barrier, thereby reducing central nervous system inflammation and demyelination. A large prospective cohort study, involving N=1,465 pregnancies with natalizumab exposure, reported no increased risk of major congenital malformations (MCMs) compared to disease-matched controls. The rate of MCMs was 2.8% (95% CI, 2.0-3.8), which is consistent with the background rate in the general population.¹ Furthermore, no specific pattern of malformations was identified. Other adverse pregnancy outcomes, such as spontaneous abortion, preterm birth, and low birth weight, were also not significantly increased.¹ The study population included women with relapsing-remitting MS who continued natalizumab treatment into pregnancy, with varying durations of exposure during the first trimester. Data collection involved detailed medical record reviews, patient interviews, and standardized reporting forms, ensuring comprehensive capture of pregnancy outcomes.

Ocrelizumab, a humanized monoclonal antibody targeting CD20-positive B cells, is approved for both relapsing-remitting MS (RRMS) and primary progressive MS (PPMS). Ocrelizumab selectively depletes CD20-expressing B cells, which play a central role in the pathogenesis of MS through antigen presentation, cytokine production, and antibody secretion. Data from a global safety database and post-marketing surveillance have accumulated regarding ocrelizumab exposure during pregnancy. An analysis of N=1,050 pregnancies with ocrelizumab exposure reported a rate of MCMs of 2.5% (95% CI, 1.7-3.5), again aligning with general population rates.² No specific teratogenic signal was observed. The data also indicated no increased risk of spontaneous abortions or stillbirths. While transient lymphopenia in neonates exposed to ocrelizumab in utero has been reported, this typically resolves spontaneously within the first year of life and is not associated with increased infection rates.² The analysis included pregnancies from various geographical regions, encompassing a diverse patient population with different MS disease courses and treatment histories. The primary limitation of these observational studies lies in their non-randomized nature, which introduces the potential for confounding by indication, where women with more stable disease might be more likely to continue treatment. Additionally, the precise timing and duration of drug exposure during critical periods of fetal development can vary, potentially influencing outcomes. Despite these limitations, the large sample sizes and consistent findings across different data sources enhance the reliability of the conclusions.

These data represent a significant expansion of the evidence base for these high-efficacy DMTs. The consistent findings across multiple cohorts and registries provide a more robust understanding of their safety profiles during pregnancy than previously available. The absence of a discernible teratogenic signal for either natalizumab or ocrelizumab is a key takeaway for clinicians and patients. While the number of exposed pregnancies is substantial, it is important to note that these are observational data, and inherent limitations, such as confounding by indication and potential for incomplete reporting, exist. However, the consistency of findings across different data sources strengthens the conclusions. Future research, including long-term follow-up of exposed children, will further refine our understanding of any subtle or delayed effects. This continued monitoring is crucial for detecting any rare or long-term adverse events that may not be apparent in initial observational studies. The evolving landscape of MS treatment necessitates ongoing data collection and analysis to ensure that women with MS can make informed decisions about their treatment during pregnancy, balancing disease control with fetal safety.